There are 1076 resources available
638P - Dacomitinib with or without dose titration in treatment naïve advanced EGFR mutated NSCLC: Primary analysis of the ATORG-003 phase II trial
Presenter: Aaron Tan
Session: Poster Display session
Resources:
Abstract
639P - A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)
Presenter: Motoko Tachihara
Session: Poster Display session
Resources:
Abstract
640P - Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
Presenter: Byoung Chul Cho
Session: Poster Display session
Resources:
Abstract
641P - METRIX: International real-world study of c-Met protein overexpression in patients with non-small cell lung cancer
Presenter: Hidehito Horinouchi
Session: Poster Display session
Resources:
Abstract
642P - Phase II trial of lazertinib plus pemetrexed/carboplatin in patients with EGFR-mutant recurrent or metastatic non-small cell lung cancer who failed prior lazertinib (LUCAS): Interim analysis
Presenter: Min Hee Hong
Session: Poster Display session
Resources:
Abstract
643P - Resistance mechanisms and efficacy of first-line (1L) alectinib in patients (pts) with ALK-rearranged non-small cell lung cancer (ALK+ NSCLC): Second interim analysis of ALCURE
Presenter: Atsuto Mouri
Session: Poster Display session
Resources:
Abstract
644P - Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study
Presenter: Dongqing Lv
Session: Poster Display session
Resources:
Abstract
645P - The Impact of driver gene alteration type on the efficacy of immune checkpoint inhibitors
Presenter: Hajime Tsuruoka
Session: Poster Display session
Resources:
Abstract
646P - Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study
Presenter: Wen Feng Fang
Session: Poster Display session
Resources:
Abstract
647P - A phase Ib/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer
Presenter: Yanwei Zhang
Session: Poster Display session
Resources:
Abstract